Stocktoria
Scholar Rock Holding Corp SRRK
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-05-24
Scholar Rock Holding Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | $33.2M | $18.8M |
| R&D expense | $208.4M | $184.6M | $121.9M | $124.4M | $108.5M |
| Operating income | -$384.6M | -$252.1M | -$171.3M | -$134.4M | -$129.9M |
| Net income | -$377.9M | -$246.3M | -$165.8M | -$134.5M | -$131.8M |
| EPS (diluted) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 |
| Operating cash flow | -$300.0M | -$200.9M | -$145.2M | -$132.7M | -$126.8M |
| Free cash flow | -$300.6M | -$201.0M | -$145.3M | -$133.8M | -$132.0M |
| Cash & equivalents | $323.5M | $177.9M | $101.9M | $103.3M | $212.8M |
| Total assets | $404.3M | $474.9M | $311.0M | $358.2M | $304.4M |
| Total liabilities | $158.8M | $106.3M | $85.8M | $97.9M | $132.4M |
| Shareholders' equity | $245.5M | $368.6M | $225.2M | $260.2M | $172.1M |
Source: SEC EDGAR filings · CIK 0001727196 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.